87 participants
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-10-27
- Start Date:
- 2020-01-03
- Completion:
- 2020-11-12
Conditions
- Hepatitis C Virus Infection
Interventions
- DRUG